NICE finalises support for CSL's HAE therapy Andembry
CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.
Sanofi, Orano cue up filings for GEP-NET radioligand therapy
Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
J&J on the hook for $966m damages in latest talc lawsuit
Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer.
Boehringer bags FDA okay for new pulmonary fibrosis drug
Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?
After FDA exit, Peter Marks pops up at Lilly
The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
6th Age-Related Disease Therapeutics Summit
Translating Aging Science into a Clinical Reality
7th CNS Drug Delivery Summit
Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond
Targeted Therapies Partnering & Licensing Summit Asia
Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh
Measuring Patient Engagement Summit Europe
The World’s Only Patient Engagement Measurement Summit is coming to Europe!
Axtria and Kedaara Capital Announce Strategic $240 Million I...
The transaction delivers total liquidity of $240 million, making it one of the largest employee-centric liquidity events in the industry.